WallStSmart

Abbott Laboratories (ABT)vsiTonic Holdings Ltd. (ITOC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 8906655% more annual revenue ($46.59B vs $523,030). ABT leads profitability with a 11.7% profit margin vs 0.0%. ABT earns a higher WallStSmart Score of 52/100 (C-).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ITOC

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.5
Piotroski: 1/9Altman Z: 2.82
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$105.62

$32.27 premium

UndervaluedFair: $73.35Overvalued

Intrinsic value data unavailable for ITOC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

ITOC3 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
91.6%10/10

Revenue surging 91.6% year-over-year

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

ITOC4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.55M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : ITOC

The strongest argument for ITOC centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 91.6% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : ITOC

The primary concerns for ITOC are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while ITOC is a hypergrowth play — different risk/reward profiles.

ITOC is growing revenue faster at 91.6% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (52/100 vs 33/100) and 13.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

iTonic Holdings Ltd.

HEALTHCARE · MEDICAL DEVICES · USA

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy.

Want to dig deeper into these stocks?